Objective To define the clinical characteristics, management, and outcome of neurologic
immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs). Methods …

Immune checkpoint inhibitors (ICIs) targeting CTLA4 and PD1 constitute a promising class of
cancer treatment but are associated with several immune-related disorders. We here review …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …

Objective Immune checkpoint inhibitors (ICI s) are improving prognoses in advanced stage
cancers, but they also lead to immune‐related adverse events (IRAE s). IRAE s targeting …

Background Combined immune checkpoint blockade (ICB) provides unprecedented efficacy
gains in numerous cancer indications, with PD-1 inhibitor nivolumab plus CTLA-4 inhibitor …

Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the
family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new …

Recent experimental and genetic studies have implicated the role of programmed cell death
protein 1 (PD-1), programmed cell death protein-ligand 1 (PDL-1), and cytotoxic T …

Background The risk of delayed autoimmunity occurring months or years after
discontinuation of immunotherapy is frequently asserted in the literature. However, specific …

Patients with advanced malignancies treated with immune checkpoint inhibitors are at
increased risk for developing immune-related neurological complications. It is a …

Background Despite unprecedented efficacy across multiple tumor types, immune
checkpoint inhibitor therapy is associated with a unique and wide spectrum of immune …